기관지 천식환자에서 Ipratropium Bromide의 효과

The Bronchodilatory Effect of Ipratropium Bromide On Bronchial Asthma - A randomized double blind study

  • 안재희 (영남대학교 의과대학 내과학교실) ;
  • 김태년 (영남대학교 의과대학 내과학교실) ;
  • 이영현 (영남대학교 의과대학 내과학교실) ;
  • 정재천 (영남대학교 의과대학 내과학교실) ;
  • 이현우 (영남대학교 의과대학 내과학교실)
  • Ahn, Jae-Hee (Department of Internal Medicine, Yeungnam University, College of Medicine) ;
  • Kim, Tae-Nyeon (Department of Internal Medicine, Yeungnam University, College of Medicine) ;
  • Lee, Young-Hyeun (Department of Internal Medicine, Yeungnam University, College of Medicine) ;
  • Chung, Jae-Chun (Department of Internal Medicine, Yeungnam University, College of Medicine) ;
  • Lee, Hyun-Woo (Department of Internal Medicine, Yeungnam University, College of Medicine)
  • 발행 : 1988.12.30

초록

Ipratropium bromide(IP) is a new anticholinergic bronchodilator To evaluate its effect on bronchial asthma which is still unkown in Korea, a double blind and randomized study was done on all patients of bronchial asthma who visit out-patients clinic of our department from June to September 1987 and showed 75 to 100% of FEV1 / FVC ratio (On pre bronchodilator spirometry(pre BD). The selected patients were given 2 puffs of Fenoterol(FE) or Ipratropium inhalator blindly and Spirometry The repeated results are: 1. In both FE and IP groups, there was a significant bronchodilatory effect on 5 and 60 minutes after administration. 2. On 5 minutes, effect of FE was significantly greater than IP.(FVC p<0.05, FEV1 p<0.01) 3. On 60 minutes, effect of IP was slightly less than FE but statistically non-significant. On the basis of above results, we concluded that onset of effect of IP is slower than FE, but its effect is significant and nearly comparable to FE.

키워드